Targacept (TRGT) -10.3% premarket after announcing revised top-line results from its exploratory...

|By:, SA News Editor

Targacept (TRGT) -10.3% premarket after announcing revised top-line results from its exploratory Phase 2 study of TC-6987 in asthma show it no longer achieves protocol-defined success criteria on the primary endpoint of Forced Expiratory Volume.